AU2012267797A1 - Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof - Google Patents

Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof Download PDF

Info

Publication number
AU2012267797A1
AU2012267797A1 AU2012267797A AU2012267797A AU2012267797A1 AU 2012267797 A1 AU2012267797 A1 AU 2012267797A1 AU 2012267797 A AU2012267797 A AU 2012267797A AU 2012267797 A AU2012267797 A AU 2012267797A AU 2012267797 A1 AU2012267797 A1 AU 2012267797A1
Authority
AU
Australia
Prior art keywords
group
optionally
substituted
oxadiazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012267797A
Other languages
English (en)
Other versions
AU2012267797A2 (en
Inventor
Nana GOTO
Junya Ikeda
Masato Iwata
Kazuhiro Mizuno
Takanori Nakamura
Hiromichi OTAKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of AU2012267797A1 publication Critical patent/AU2012267797A1/en
Publication of AU2012267797A2 publication Critical patent/AU2012267797A2/en
Assigned to SUMITOMO DAINIPPON PHARMA CO., LTD. reassignment SUMITOMO DAINIPPON PHARMA CO., LTD. Alteration of Name(s) of Applicant(s) under S113 Assignors: DAINIPPON SUMITOMO PHARMA CO., LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2012267797A 2011-06-07 2012-06-06 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof Abandoned AU2012267797A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011127688 2011-06-07
JP2011-127688 2011-06-07
PCT/JP2012/065052 WO2012169649A1 (en) 2011-06-07 2012-06-06 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
AU2012267797A1 true AU2012267797A1 (en) 2014-01-09
AU2012267797A2 AU2012267797A2 (en) 2014-05-22

Family

ID=47296200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012267797A Abandoned AU2012267797A1 (en) 2011-06-07 2012-06-06 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof

Country Status (12)

Country Link
US (1) US20140057895A1 (enExample)
EP (1) EP2718283A4 (enExample)
JP (1) JP2014510708A (enExample)
KR (1) KR20140041519A (enExample)
CN (1) CN103748087A (enExample)
AU (1) AU2012267797A1 (enExample)
BR (1) BR112013030939A2 (enExample)
CA (1) CA2833507A1 (enExample)
MX (1) MX2013014427A (enExample)
RU (1) RU2013157374A (enExample)
TW (1) TW201311674A (enExample)
WO (1) WO2012169649A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016028016A (ja) * 2012-12-12 2016-02-25 大日本住友製薬株式会社 オキサジアゾール誘導体とその医薬用途
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR102140508B1 (ko) 2016-09-28 2020-08-03 경희대학교 산학협력단 헌팅턴병의 예방 또는 치료용 조성물
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EP3914592A1 (en) * 2019-01-25 2021-12-01 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN116836157A (zh) * 2022-03-25 2023-10-03 星希尔生物科技(上海)有限公司 一种噁二唑衍生物及其制备方法和用途
CN115417772B (zh) * 2022-09-26 2024-07-19 无锡双启科技有限公司 一种3-硝基-4-氟苯甲醚的制备方法
CN115947690B (zh) * 2022-12-13 2025-04-08 安徽医科大学 一种吲唑分子砌块的制备方法及其在药物合成中的应用
WO2025045837A1 (en) 2023-08-31 2025-03-06 Syngenta Crop Protection Ag Pesticidally active indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
ES2347265T3 (es) * 2004-12-22 2010-10-27 Theravance, Inc. Compuestos de indazol-carboxamida.
JP5075818B2 (ja) * 2005-07-22 2012-11-21 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのインダゾールカルボキサミド誘導体
GB0614070D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0901487D0 (en) * 2009-01-30 2009-03-11 Movetis N V Asthma Therapy
EP2643311A1 (en) * 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
MX337721B (es) * 2011-09-19 2016-03-16 Suven Life Sciences Ltd Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Also Published As

Publication number Publication date
KR20140041519A (ko) 2014-04-04
CN103748087A (zh) 2014-04-23
MX2013014427A (es) 2014-01-23
US20140057895A1 (en) 2014-02-27
AU2012267797A2 (en) 2014-05-22
RU2013157374A (ru) 2015-07-20
CA2833507A1 (en) 2012-12-13
BR112013030939A2 (pt) 2016-12-06
JP2014510708A (ja) 2014-05-01
TW201311674A (zh) 2013-03-16
EP2718283A4 (en) 2014-10-29
WO2012169649A1 (en) 2012-12-13
EP2718283A1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
AU2012267797A1 (en) Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
AU2018243691B2 (en) Heterocyclic compound
AU2008241091B2 (en) Quinoline-carboxamide derivatives as P2Y12 antagonists
JP2013010719A (ja) ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
DK2545045T3 (en) PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS
ES2425091T3 (es) Benzoxazepinas como inhibidores de PI3K/mTOR y sus métodos de uso y fabricación
AU2007281678B2 (en) 2-aminobenzoxazole carboxamides as 5HT3 modulators
AU2021201018A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
KR20220130127A (ko) Trpml 조절제
CA3098585A1 (en) Pyridazinones as parp7 inhibitors
CA2889526C (en) 2-aminopyridine compounds
CA2898440A1 (en) Phthalazinones and isoquinolinones as rock inhibitors
TW201002685A (en) Heterocyclic compound and use thereof
EA017144B1 (ru) N-содержащие бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
BR112014006283B1 (pt) Novos derivados de dihidroquinolina-2-ona
KR20220079882A (ko) Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로시클릭 화합물
WO2014092104A1 (ja) オキサジアゾール誘導体とその医薬用途
KR20180016485A (ko) 무스카린성 m2 수용체의 양성 알로스테릭 조정제
CA3235504A1 (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
EP4476211A1 (en) Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
WO2022152852A1 (en) Antagonists of mrgx2
JP2014133739A (ja) インダゾール誘導体またはピロロピリジン誘導体からなる医薬
JP2024502301A (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
TW202400589A (zh) 四氫異喹啉異雙功能ｂｃｌ—ｘｌ降解劑
TW202309006A (zh) 作為ｓｉｇｍａ配體的新穎吡啶磺醯胺衍生物、其製備方法及用途，以及包含該吡啶－磺醯胺衍生物的醫藥組成物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JAN 2014; 08 APR 2014

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period